| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H78N6O13 |
| Molecular Weight | 887.1118 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@](O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCCCNC(=O)CCCCCCCCCCCCCCCCC)C(O)=O)C(N)=O)([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O
InChI
InChIKey=IKSJCVFYCIKDTB-GZZWOGMVSA-N
InChI=1S/C43H78N6O13/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23-36(54)45-26-21-20-22-33(43(60)61)48-37(55)25-24-32(40(44)57)49-41(58)29(2)46-42(59)30(3)62-39(38(56)35(53)28-51)34(27-50)47-31(4)52/h27,29-30,32-35,38-39,51,53,56H,5-26,28H2,1-4H3,(H2,44,57)(H,45,54)(H,46,59)(H,47,52)(H,48,55)(H,49,58)(H,60,61)/t29-,30+,32+,33-,34-,35+,38+,39+/m0/s1
Romurtide (Muroctasin) is a non-specific immune stimulant derived from muramyl dipeptide, which is obtained from gram-positive bacterial cell walls. Muroctasin stimulates macrophages, which release interleukin-l, which in turn increases production of colony-stimulating factors; muroctasin also evokes an increased production of neutrophils. It is used in Japan for chemotherapy-induced leukopenia.
Originator
Approval Year
PubMed
Sample Use Guides
For the treatment of leukopenia and thrombopenia 200 ug of Romurtide (muroctasin) for 6 days post-chemotherapy.
Route of Administration:
Intravenous
ACTIVE MOIETY
